Liu F, Pinz K, Ma Y, et al. First-in-human CLL1-DC33 compound CAR T cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia. EHA 2018; abstract S149.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom